Navigation Links
OXYMATIC® 401 Electronic Oxygen Conserver

ProductsOXYMATIC® 401 Electronic Oxygen Conserver
Company CHAD Therapeutics, Inc.
Item OXYMATIC® 401 Electronic Oxygen Conserver
Features 
  • Alternate Breath Delivery with Built-In Brass Regulator (Continuous flow preset at 2 lpm)
  • Weighs approximately 1.8 lbs (816 grams) with the battery
  • Provides every-breath or alternate-breath delivery with a built-in regulator.
  • Offers 1-6 lpm flow equivalency settings to service a broad range of patients.
  • Delivers fixed pulse of oxygen within the first 200 milliseconds of inspiration.
  • Easy access to the battery compartment.
    • Description An All-In-One Conserver.

    Offers an average 5:1 increase in usage time at all settings.

    Allows the use of a standard cannula.

    The combination of the OXYMATIC conserver and lightweight cylinders offers ambulatory oxygen patients a superior alternative to liquid oxygen.

    Reliability backed by a 2-year warranty.

    NOTE: Each model has passed the ASTM PS 127-00 regulator ignition safety test.
    Info CHAD Therapeutics, Inc.
    Customer Service: (800) 423-8870
    Web site: http://www.chadtherapeutics.com

    Related medicine products :

    1. OXYMATIC® 401A Electronic Oxygen Conserver
    2. OXYMATIC® 411A Electronic Oxygen Conserver
    3. OXYMATIC® 411 Electronic Oxygen Conserver
    4. OXYMATIC® 411AF Electronic Oxygen Conserver
    5. SEQUOIA OXYMATIC® 302 Electronic Oxygen Conserver
    6. SEQUOIA OXYMATIC® 312 Electronic Oxygen Conserver
    7. OXYMATIC® 2400 Electronic Oxygen Conserver
    8. SEQUOIA OXYMATIC® 311 Electronic Oxygen Conserver
    9. MaximEyes Practice Management and Electronic Medical Records Software Solutions
    10. PRAXIS® Electronic Medical Records v. 2.19
    11. MaximEyes Optometric & Ophthalmology Software for Practice Management and Electronic Medical Records
    Breaking Medicine Technology:Circassia Raises GBP15 Million ($25 Million) in Oversubscribed Investment Round 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 3Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 4Sinovac Establishes Joint Venture to Expand Human Use Vaccine Development and Manufacturing Capabilities 14977 1Sinovac Establishes Joint Venture to Expand Human Use Vaccine Development and Manufacturing Capabilities 14977 2Sinovac Establishes Joint Venture to Expand Human Use Vaccine Development and Manufacturing Capabilities 14977 3Abaxis Inc to Present at the 21st Annual Piper Jaffray Health Care Conference 6535 1Cempra Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 6531 1